Boston Scientific (NYSE: BSX) — Perfil da empresa, notícias e dados financeiros
Boston Scientific develops medical devices to improve patient outcomes across various interventional specialties globally.
Boston Scientific
Boston Scientific is a global medical device manufacturer that develops, manufactures, and markets medical solutions used in a range of interventional medical specialties. The company's products are utilized in interventional cardiology, electrophysiology, peripheral interventions, vascular surgery, gastroenterology, pulmonology, urology, pelvic health, and neurological surgery. Its medical technologies assist physicians in diagnosing and treating complex cardiovascular conditions, chronic pain, neurological disorders, and gastrointestinal conditions. Headquartered in Marlborough, Massachusetts, the company serves healthcare institutions, hospitals, and medical professionals worldwide across North America, Europe, Asia-Pacific, Latin America, and Middle East regions.
Resumo
Operações
Produtos e/ou serviços de Boston Scientific
- Interventional Cardiology: Manufacturing and distribution of coronary stent systems, balloon catheters, intravascular imaging devices, and structural heart devices including transcatheter aortic valves and left atrial appendage closure systems for treating coronary artery disease and structural heart conditions worldwide.
- Electrophysiology: Provision of cardiac mapping platforms, diagnostic catheters, radiofrequency ablation systems, and cryoablation technologies used by electrophysiologists to diagnose and treat cardiac arrhythmias, atrial fibrillation, and complex rhythm disorders in hospital and clinical settings globally.
- Neuromodulation: Development and production of deep brain stimulation systems and spinal cord stimulation devices, alongside radiofrequency ablation generators, designed to treat chronic pain, Parkinson's disease, movement disorders, and intractable neurological symptoms in patients worldwide.
- Endoscopy: Supply of advanced gastrointestinal and pulmonary devices, including esophageal stents, enteral feeding tubes, biliary catheters, and single-use duodenoscopes used for diagnosing and treating disorders of the digestive tract, liver, and respiratory systems.
- Urology and Pelvic Health: Delivery of laser therapy systems, water vapor therapy units, penile implants, and urinary incontinence surgical products to treat benign prostatic hyperplasia, erectile dysfunction, kidney stones, and pelvic floor disorders in clinical practice.
- Peripheral Interventions: Production of drug-eluting vascular stents, thrombectomy systems, atherectomy devices, embolization coils, and radioembolization microspheres utilized by interventional radiologists and vascular surgeons to clear arterial blockages, manage deep vein thrombosis, and treat localized cancers.
equipe executiva do Boston Scientific
- Michael F. MahoneyChairman, President & CEO
- Jonathan R. MonsonExecutive VP & CFO
- Vance R. BrownEVP, General Counsel & Corporate Secretary
- Joseph M. FitzgeraldExecutive VP & Group President of Cardiovascular
- Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific
- Paudie O'ConnorExecutive Vice President of Global Operations
- Emily M. WoodworthSenior VP, Global Controller & Chief Accounting Officer
- Adam SmithGeneral Manager of Global Sales & Marketing
- Miriam O'sullivanSenior VP & Chief Human Resources Officer
- Brenda BeckerSenior Vice President of Global Government Affairs
Últimas notícias sobre a Boston Scientific
Boston Scientific Q3 revenue revs up 1.5% to $5.14 billion
United StatesBoston Scientific second-quarter sales reach $5.442 billion
United StatesBoston Scientific coronary catheter meets targets in pivotal trial
United StatesBoston Scientific sales surpass $5.2B as cardiovascular growth drives Q1
United StatesBoston Scientific profit gains as electrophysiology sales drive double-digit growth
United StatesBoston Scientific to acquire Penumbra in $14.5B deal
United States
Principais indicadores financeiros
Resultados divulgados pela Boston Scientific , em USD.
- Cap. de mercado
- 65,3 bi
- Receita (TTM)
- 21 bi
- P/L
- 18.2
- LPA (diluído, TTM)
- 2.5
- Dividend yield
- —
- Margem de lucro
- 17.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 20,1 bi | 4 bi | 2,9 bi | |
| 16,7 bi | 2,6 bi | 1,9 bi | |
| 14,2 bi | 2,2 bi | 1,6 bi | |
| 12,7 bi | 1,8 bi | 698 mi |